Fig. 3

Effects of checkpoint inhibitor (CPI) therapy on the odds ratios of survival (95% CI) in each of the 19 analyzed experiments in three subgroups with its I² and level of significance. The subgroups are based on whether experiments included a bacterial challenge alone without antibiotic therapy, a bacterial challenge alone with antibiotic therapy directed at the bacterial challenge or a bacterial challenge with antibiotic therapy directed at the bacterial challenge followed by a C. albicans challenge 3 to 4 days later, as well as the overall OR and its I² with level of significance for each subgroup. Also shown are the times the CPI therapy was administered relative to the bacterial challenge. *CPI administered at D−1; **CPI administered at D0; ^#anti-CTLA-4 50 μg in CD-1 mice; ^##anti-CTLA-4 200 μg CD-1 mice; ^C57BL6 mice; ^@C57BL6 mice; ^@@Bmal-/- mice. CA—Candida albicans; PD-1—programmed cell death 1; PD-L1—programmed cell death ligand-1; CTLA-4—cytotoxic T lymphocyte-associated protein-4; BTLA—B and T lymphocyte attenuator; CPM—checkpoint molecule targeted; CLP—cecal ligation and puncture which represented polymicrobial organisms; IV—intravenous; IP—intraperitoneal; LPS—lipopolysaccharide; L. mono—Listeria monocytogenes; P. aerug—Pseudomonas aeruginosa; S. aur—Staphylococcus aureus